ATLASATLAS fair value
$87.73
Above fair value · 46% premium
Range: $77–$99Fair valuePrice
Halozyme Therapeutics (HALO)
Halozyme Therapeutics stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$128.50▲ +0.38%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Halozyme Therapeutics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Halozyme Therapeutics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Halozyme Therapeutics's fair value at about $87.73 per share (reasonable range: $76.92 to $99.06). At $128.50, the stock trades 46% above it.
It is calculated with valuation multiples of comparable companies. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Halozyme Therapeutics a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $121.01 and $136.64; in 9 out of 10, between $108.65 and $152.17. Estimated annual volatility is 34%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $12.5B
- P/E ratio
- 30.3
- 52-week high
- $128.65
- 52-week low
- $61.23
- Revenue (12 months)
- $1.7B
- Revenue growth (YoY)
- +37.6%
- Earnings growth (YoY)
- -25.4%
- Gross margin
- 83.6%
- Operating margin
- 57.5%
- Net margin
- 22.7%
- Return on equity
- 173.7%
- Free cash flow (12 months)
- $337M
- Beta
- 0.88
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Halozyme Therapeutics sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks HALO has traded between $61.23 and $128.65. Today it is at its high and 110% above its low.
On the business: revenue grew 37.6% year over year; net margin is 22.7%; it trades at 30.3 times earnings.
Its beta is 0.88: it moves roughly in line with the market.
About the company
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines.
Want to see everything about Halozyme Therapeutics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Halozyme Therapeutics (HALO) fair value?
About $87.73 per share according to ATLAS (reasonable range: $76.92 to $99.06). With the stock at $128.50, it is 46% above it.
What is the chance HALO goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, HALO ends the month between $121.01 and $136.64.
How big is Halozyme Therapeutics and what is its P/E ratio?
Halozyme Therapeutics's market capitalization is $12.5B. Its price-to-earnings (P/E) ratio is 30.3: you pay $30.3 for each $1 of yearly earnings.
How volatile is HALO?
ATLAS estimates annual volatility at 34%. In a typical month, half of the outcomes end between $121.01 and $136.64.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer